Apolipoprotein D (ApoD) In Human Serum As Marker Of Parkinson's Disease — ApoD  

Parkinson's Clinical Trial

Official title: Detection of Apolipoprotein D (ApoD) in Human Serum as Marker of Parkinson's Disease

Status Enrolling by invitation

Clinical Trial Summary

In Italy affected people are 200,000 and every year Parkinson new cases are 10,000. Aging is the principle risk factor of Parkinson with the possibility of its development doubling every five years after 65. Because of the increase of the social longevity and aging as the main risk factor, there are many repercussions on the health system (hospital stays and pharmaceutical costs) as on the social system (assistance- related problems). Parkinson's disease exerts an extremely negative impact on life's quality of the patient. In fact, because of Parkinson symptoms (tremor, dribble, etc), patient's social life will be reduced with the consequent development of the depression. Consequently, the early detection and treatment of Parkinson's is necessary.

To achieve this goal, Apolipoprotein D (ApoD) in human serum as a marker of the oxidative stress-inflammation vicious cycle seems most promising candidate for diagnosis.

Clinical Trial Description

Total participants: n=180.

Study Part 1:

Health persons: n=90; Groups of health persons: n=3; Subjects per group: n=30.

Study Part 2:

Patients: n=90; Groups of patients: n=3; Subjects per group: n=30. ;

Study Design

Observational Model: Cohort

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's

• NCT number: NCT01467960
• Study type: Observational
• Source: Privatklinik Villa Melitta
• Status: Enrolling by invitation
• Phase: N/A
• Start date: November 2011
• Completion date: November 2013